733.78
+0.74(+0.10%)
Currency In USD
| Previous Close | 733.04 |
| Open | 728 |
| Day High | 738 |
| Day Low | 718.38 |
| 52-Week High | 821.11 |
| 52-Week Low | 476.49 |
| Volume | 673,259 |
| Average Volume | 1.01M |
| Market Cap | 75.79B |
| PE | 17.59 |
| EPS | 41.71 |
| Moving Average 50 Days | 741.22 |
| Moving Average 200 Days | 610.6 |
| Change | 0.74 |
If you invested $1000 in Regeneron Pharmaceuticals, Inc. (REGN) 10 years ago, it would be worth $1,589.75 as of January 21, 2026 at a share price of $733.78. Whereas If you bought $1000 worth of Regeneron Pharmaceuticals, Inc. (REGN) shares 5 years ago, it would be worth $1,370.32 as of January 21, 2026 at a share price of $733.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
GlobeNewswire Inc.
Jan 02, 2026 9:05 PM GMT
TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S.
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 22, 2025 9:05 PM GMT
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation is scheduled for 2:15
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of a cash upfront and equity investm